FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
MedCity News22h
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
AFP5d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
pharmaphorum2d
FDA approves flurry of drugs ahead of holiday season
Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab) at its second attempt, having been turned down by the US regulator last year. The tissue ...
Yahoo Finance3d
Vertex Pharmaceuticals Incorporated (VRTX)
The early approval of vanza triple, or Alyftrek, is “positive, but was largely expected,” adds the analyst, who sees upside from pipeline updates in 2025. Published first on TheFly – the ul ...